We recently compiled a list of the 10 Best ... into new therapeutic areas. Its product lineup is anchored by its oncology ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

AstraZeneca is a company with a turbulent history ... Astra introduced two important product families onto the Swedish market in 1948: penicillin and anaesthetics, initially in the form of Xylocaine.

If you're in that group, you're in luck. Three Fool.com contributors have identified what they view as magnificent stocks ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

CEO says But is the focus on combination opportunities really an excuse for AstraZeneca to take off the pressure of proving that any of its obesity products will actually be able to deliver the ...

The U.K. pharmaceutical company AstraZeneca has become the largest multinational drugmaker in China, drawing 13% of its $5.8 billion in revenue last year from there, against a backdrop of an acute ...

We recently published a list of 8 High Growth UK Stocks ... the company’s products are sold in more than 125 countries. AstraZeneca (NASDAQ:AZN) is a leader in oncology, cardiovascular, renal ...

On the first of these — the price-to-earnings ratio (P/E) — AstraZeneca is bottom of the list of its competitors ... failure in any of its major product lines, as this could prove costly ...